Search Results - "Girotti, M.R."

Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy by Smith, M.P, Brunton, H, Rowling, E.J, Girotti, M.R, Marais, R, Dummer, R, Flaherty, K.T, Cooper, Z.A, Wargo, J.A, Wellbrock, C

Get full text

Assessing the interplay of RNA-fusion events with cancer driver mutations in melanoma patients by Mandal, A, Girotti, M.R, Dhomen, N, Viros, A, Gremel, G, Galvani, E, Baenke, F, Lee, R, Lim, K.H.J, Lorigan, P, Marais, R

Get full text

Systematic longitudinal analysis of circulating tumour DNA in melanoma patients undergoing systemic therapy by Gremel, G, Lee, R.J, Girotti, M.R, Garner, G, Mandal, A.K, Valpione, S, Serra-Bellver, P, Wood, S, Fusi, A, Dhomen, N, Lorigan, P, Marais, R

Get full text

Gene-specific interactions between ultraviolet radiation and melanoma by Viriós, A, Pedersen, M, Furney, S.J, Girotti, M.R, Hogan, K, Saturno, G, Galvani, E, Sanchez-Laorden, B, Ng, C, Reis-Filho, J.S, Lorigan, P, Cook, M, Marais, R

Get full text

Tumour–microenvironment mediates resistance to immuno and targeted therapies in acral melanoma by Lee, R, Girotti, M.R, Khandelwal, G, Baenke, F, Viros, A, Mandal, A, Bridgeman, J, Galvani, E, Gremel, G, Kalaitsidou, M, Ashton, G, Peset, I, Smith, M, Hawkins, R, Fusi, A, Miller, C, Gilham, D, Dhomen, N, Lorigan, P, Marais, R

Get full text

Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma by Girotti, M.R, Gremel, G, Lee, R, Galvani, E, Rothwell, D, Mandal, A.K, Lim, K.H.J, Saturno, G, Furney, S.J, Baenke, F, Pedersen, M, Smith, M, Fusi, A, Dhomen, N, Brady, G, Lorigan, P, Dive, C, Marais, R

Get full text

Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models by Saturno, G, Lopes, F, Girotti, M.R, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Viros, A, Pedersen, M, McLeary, R, Knight, R, Lee, R, Holovanchuk, D, Fusi, A, Lorigan, P, Dhomen, N, Marais, R, Springer, C

Get full text

76 Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors by Marusiak, A.A, Edwards, Z.C, Hugo, W, Trotter, E.W, Girotti, M.R, Stephenson, N.L, Kong, X, Gartside, M.G, Fawdar, S, Hudson, A, Breitwieser, W, Hayward, N.K, Marais, R, Lo, R.S, Brognard, J

Get full text

Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients by Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M.R., Lee, R.J., Garner, G., Dhomen, N., Lorigan, P.C., Marais, R.

“…Tumour burden is a prognostic biomarker in metastatic melanoma. However, tumour burden is difficult to measure and there are currently no reliable surrogate…”
Get full text

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA by Gremel, G., Lee, R.J., Girotti, M.R., Mandal, A.K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D.G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., Marais, R.

“…The application of precision medicine in oncology requires in-depth characterisation of a patient's tumours and the dynamics of their responses to treatment…”
Get full text

5 - Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy by Smith, M.P., Brunton, H., Rowling, E.J., Girotti, M.R., Marais, R., Dummer, R., Flaherty, K.T., Cooper, Z.A., Wargo, J.A., Wellbrock, C.

Get full text

289 - Gene-specific interactions between ultraviolet radiation and melanoma by Viriós, A., Pedersen, M., Furney, S.J., Girotti, M.R., Hogan, K., Saturno, G., Galvani, E., Sanchez-Laorden, B., Ng, C., Reis-Filho, J.S., Lorigan, P., Cook, M., Marais, R.

Get full text

131 - Assessing the interplay of RNA-fusion events with cancer driver mutations in melanoma patients by Mandal, A., Girotti, M.R., Dhomen, N., Viros, A., Gremel, G., Galvani, E., Baenke, F., Lee, R., Lim, K.H.J., Lorigan, P., Marais, R.

Get full text

805 - Systematic longitudinal analysis of circulating tumour DNA in melanoma patients undergoing systemic therapy by Gremel, G., Lee, R.J., Girotti, M.R., Garner, G., Mandal, A.K., Valpione, S., Serra-Bellver, P., Wood, S., Fusi, A., Dhomen, N., Lorigan, P., Marais, R.

Get full text

836 - Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma by Girotti, M.R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Mandal, A.K., Lim, K.H.J., Saturno, G., Furney, S.J., Baenke, F., Pedersen, M., Smith, M., Fusi, A., Dhomen, N., Brady, G., Lorigan, P., Dive, C., Marais, R.

Get full text

822 - Tumour–microenvironment mediates resistance to immuno and targeted therapies in acral melanoma by Lee, R., Girotti, M.R., Khandelwal, G., Baenke, F., Viros, A., Mandal, A., Bridgeman, J., Galvani, E., Gremel, G., Kalaitsidou, M., Ashton, G., Peset, I., Smith, M., Hawkins, R., Fusi, A., Miller, C., Gilham, D., Dhomen, N., Lorigan, P., Marais, R.

Get full text

862 - Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models by Saturno, G., Lopes, F., Girotti, M.R., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Viros, A., Pedersen, M., McLeary, R., Knight, R., Lee, R., Holovanchuk, D., Fusi, A., Lorigan, P., Dhomen, N., Marais, R., Springer, C.

Get full text